Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

The Lancet

Volumn 372, Issue 9635, 2008, Pages 293-299

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG USE; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORTH AMERICA; PRIORITY JOURNAL;

EID: 47649115323     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61113-7     Document Type: Article

References (41)

1. Hammer S., Saag M., Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 (2006) 827-843
2. Grabar S., Moing V., Goujard C., et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Int Med 133 (2000) 401-410
3. Gallant J., DeJesus E., Arribas J., et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354 (2006) 251-260
4. Lange J. Efficacy and durability of nevirapine in antiretroviral drug naive patients. J Acquir Immune Defic Syndr 34 suppl 1 (2003) S40-S52
5. Montaner J., Hogg R., Wood E., et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 368 (2006) 531-536
6. Robbins G., De Gruttola V., Shafer R., et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349 (2003) 2293-2303
7. Staszewski S., Morales-Ramirez J., Tashima K., et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 341 (1999) 1865-1873
8. van Leth F., Phanuphak P., Ruxrungtham K., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363 (2004) 1253-1263
9. Chiasson M., Berenson L., Li W., et al. Declining HIV/AIDS mortality in New York City. J Acquir Immune Defic Syndr 21 (1999) 59-64
10. Detels R., Munoz A., McFarlane G., et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 280 (1998) 1497-1503
11. Hogg R., O'Shaughnessy M., Gataric N., et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 349 (1997) 1294
12. Hogg R., Heath K., Yip B., et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279 (1998) 450-454
13. Mocroft A., Vella S., Benfield T., et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352 (1998) 1725-1730
14. Moore R., and Chaisson R. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 13 (1999) 1933-1942
15. Palella Jr. F., Delaney K., Moorman A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338 (1998) 853-860
16. Vittinghoff E., Scheer S., O'Malley P., Colfax G., Holmberg S., and Buchbinder S. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 179 (1999) 717-720
17. Wong K., Chan K., and Lee S. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy. Clin Infect Dis 39 (2004) 853-860
18. Sterne J., Hernan M., Ledergerber B., et al., for the Swiss HIV Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366 (2005) 378-384
19. Braitstein P., Brinkhof M., Dabis F., et al., for the Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367 (2006) 817-824
20. McGuire A., Barer J., Montaner J., and Hogg R. There and back again: the impact of adult HIV prevalence on national life expectancies. HIV Med 6 (2005) 57-58
21. Chene G., Sterne J., May M., et al., for the Antiretroviral Therapy Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362 (2003) 679-686
22. Egger M., May M., Chene G., et al., for the ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360 (2002) 119-129
23. May M., Royston P., Egger M., Justice A., and Sterne J. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med 23 (2004) 2375-2398
24. Gardner J., and Sanborn J. Years of potential life lost (YPLL)-what does it measure?. Epidemiology 1 (1990) 322-329
25. Selik R., and Chu S. Years of potential life lost due to HIV infection in the United States. AIDS 11 (1997) 1635-1639
26. Braithwaite R., Kozal M., Chang C., et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 21 (2007) 1579-1589
27. Crum N., Riffenburgh R., Wegner S., et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 41 (2006) 194-200
28. Egger M., Hirschel B., Francioli P., et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 315 (1997) 1194-1199
29. Fang C., Chang Y., Hsu H., et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 100 (2007) 97-105
30. King Jr. J., Justice A., Roberts M., Chang C., and Fusco J. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis Making 23 (2003) 9-20
31. Lima V., Hogg R., Harrigan P., et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 21 (2007) 685-692
32. Lloyd-Smith E., Brodkin E., Wood E., et al. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 20 (2006) 445-450
33. Walensky R., Paltiel A., Losina E., et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 194 (2006) 11-19
34. Lewden C., Salmon D., Morlat P., et al. Causes of death among HIV-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 34 (2005) 121-130
35. Valdez H., Chowdhry T., Asaad R., et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis 32 (2001) 1487-1493
36. Bonnet F., Morlat P., Chene G., et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 3 (2002) 195-199
37. Sterne J., May M., Sabin C., et al. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. J Acquir Immune Defic Syndr 46 (2007) 607-615
38. Arnsten J., Demas P., Grant R., et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 17 (2002) 377-381
39. Staehelin C., Egloff N., Rickenbach M., Kopp C., and Furrer H. Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: a single center study of epidemiologic migration-specific and clinical features. AIDS Patient Care STDs 18 (2004) 665-675
40. May M., Sterne J., Costagliola D., et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 368 (2006) 451-458
41. Lohse N., Hansen A.-B., Pedersen G., et al. Survival of persons with and without HIV Infection in Denmark, 1995-2005. Ann Intern Med 146 (2007) 87-95